Carl Zeiss Meditec AG reaffirmed earnings guidance for the year 2021/22. For the year 2021/22, the company's revenue is expected to grow at least to the same extent as the market.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
93 EUR | -1.64% | -7.00% | -5.91% |
May. 10 | CARL ZEISS MEDITEC AG : Hauck & Aufhauser gives a Buy rating | ZD |
May. 09 | CARL ZEISS MEDITEC AG : Deutsche Bank sticks Neutral | ZD |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.91% | 9.11B | |
+11.29% | 226B | |
+8.76% | 188B | |
+12.90% | 137B | |
+25.95% | 108B | |
+0.34% | 63.19B | |
+11.08% | 52.26B | |
+5.62% | 51B | |
+6.28% | 43.89B | |
+4.80% | 38.07B |
- Stock Market
- Equities
- AFX Stock
- News Carl Zeiss Meditec AG
- Carl Zeiss Meditec AG Reaffirms Earnings Guidance for the Year 2021/22